

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1.     *(Currently amended)* A method for treating stroke said method comprising:
  - a) administering as a single dose a defibrinogenating agent to a ~~patient~~ human in need of such treatment at a rate of about 0.05- 1.25 IU/kg/hr, wherein said rate is sufficient to achieve rapid initial defibrinogenation;
  - b) ceasing administration of said defibrinogenating agent after about 15 min to 12 hours; and
  - b) allowing normalization of fibrinogen levels to occur without further administration of said defibrinogenating agent.
  
2.     *(Original)*     The method of claim 1, wherein initial defibrinogenation occurs at a rate of  $\geq 20$  mg/dL/hr.
  
3.     *(Original)*     The method of claim 1, wherein initial defibrinogenation occurs at a rate of  $\geq 30$  mg/dL/hr.
  
4.     *(Currently amended)* The method of claim 1, wherein the defibrinogenating agent is anacrod.
  
5.     *(Canceled)*
  
6.     *(Original)*     The method of claim 1 wherein the defibrinogenating agent is administered as a single dose of about 0.1- 0.2 IU/kg/hr.
  
7.     *(Original)*     The method of claim 1 wherein the defibrinogenating agent is administered as a single dose at a rate of about 0.14-0.175 IU/kg/hr.

8.     *(Original)*     The method of claim 1 where the defibrinogenating agent is administered intravenously.
9.     *(currently amended)*   A method for treating stroke said method comprising:
- a) administering a defibrinogenating agent to a human patient in need of such treatment at a rate of about 0.10-1.5 IU/kg/hr;
  - b) ceasing administration of the defibrinogenating agent after about 15 min to 12 hours; and
  - c) allowing normalization of fibrinogen levels to occur without further administration of said defibrinogenating agent.
10.    *(Original)*     The method of claim 9 wherein said defibrinogenating agent is administered from about 30 minutes to 6 hours.
11.    *(Original)*     The method of claim 9 where the defibrinogenating agent is administered intravenously.